Aliskiren and the dual complement inhibition concept
Keyword(s):
Abstract In this issue of Clinical Kidney Journal, Plasse et al. report on the use of high-dose aliskiren as an adjunct therapy in a patient treated with eculizumab for haemolytic uraemic syndrome (HUS). This follows the recent description of the complement factor 3 (C3) activating activity of the enzyme renin and the successful therapeutic use of the direct renin inhibitor aliskiren in three cases of C3 glomerulopathy/dense deposit disease. We discuss the potential clinical and pathophysiological implications of these reports on nephropathies linked to complement, from HUS to C3 glomerulopathy to immunoglobulin A nephropathy as well as the concept of dual complement inhibition for kidney disease.
2015 ◽
2015 ◽
Vol 54
(24)
◽
pp. 3127-3132
◽
Keyword(s):
2020 ◽
Vol 5
(4)
◽
pp. 160-163
2006 ◽
Vol 146
(1)
◽
pp. 47-53
◽